An observational study in Covid-19, Coronavirus Infection and Coronavirus, sponsored by Columbia University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Columbia University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in COVID-19 by Columbia University — 2 open to participants now, 4 under way, none of them phase 3. COVID-19 · Columbia University.
Among the 23 studies in COVID-19 by Columbia University, this one is the 3rd largest by planned enrollment of the 13 observational ones that give a count, is one of 12 that started in 2020, is one of 13 observational ones, and was the 5th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →2 of the 23 studies in COVID-19 by Columbia University are open now, in 1 country. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 7+
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2020; this study’s year is marked. 12 started in 2020.
This study's planned enrollment of 1,000 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 38 across the 10 interventional studies, 154 across the 13 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
4 of the studies in COVID-19 by Columbia University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05467917Columbia UniversityARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases | 2026-12 |
| NCT04367857Columbia UniversityARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers | 2027-02 |
| NCT05467930Columbia UniversityCU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2 | 2027-05 |
| NCT04448145Columbia UniversityDeterminants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 23 studies in COVID-19 by Columbia University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The novel coronavirus (SARS-CoV-2) has spread all around the world and testing has posed a challenge globally. Health care providers are highly exposed and are an important group to test. On top of these concerns, health care workers are also stressed by the needs on responders in the COVID-19 crisis. The investigators will look at different ways to measure how common COVID-19 is among health care workers, how common is the presence of antibodies by serological tests (also known as serostatus). The investigators will describe health worker mental and emotional well-being and their coping strategies in their institutional settings. Lastly, the investigators will describe how knowing serostatus can affect individuals' mental and emotional well-being and how to cope in the midst of the COVID-19 response. This will help to how to better test and help healthcare workers in the COVID-19 pandemic and prepare for possible future outbreaks.
The rapid spread of the novel coronavirus SARS-CoV-2 has resulted in pandemic levels and a global challenge in diagnosing infection. Diagnosing infection, defining recovery and immunity has been challenging. Health care providers in particular are very interested in knowing their status as they are highly exposed, and if infectious, can potentially transmit infection nosocomially (in the healthcare workplace setting) and to their household. In addition to understanding their exposure risk, infectious period, and immunity status, health care workers are reporting high levels of psychosocial distress including anxiety and burnout. The investigators aim to assess the baseline and cumulative seroprevalence of SARS-CoV-2 among health care workers using both quantitative and qualitative serological assays; describe psychosocial well-being and coping strategies among health workers in their institutional settings and describe how knowledge of one's serostatus affect psychosocial well-being, and coping strategies. Findings from this study will inform; 1) use of serological assays and testing algorithms, and 2) approaches to manage psychosocial stress for healthcare workers.
Employee of NewYork-Presbyterian Hospital and its affiliates
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prior Positive PCR result, fully recovered, back at work and symptom free for greater than or equal than 14 days.
Other: COVID-19 Serology · Behavioral: Health Care Worker Survey
Never tested and history of COVID-19 symptoms and symptom-free for more than 14 days
Other: COVID-19 Serology · Behavioral: Health Care Worker Survey
Never tested and current COVID-19 Symptoms (e.g. referred by a provider or clinic)
Other: COVID-19 Serology · Behavioral: Health Care Worker Survey
Never tested and asymptomatic for COVID-19 symptoms, including asymptomatic health care worker
Other: COVID-19 Serology · Behavioral: Health Care Worker Survey
Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19
The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.
Proportion seropositive
Percentage of health care workers with positive serological markers to describe patterns in exposure, re-infection, clinical symptom, serological responses among health care workers based on their baseline serological status over a one year period.
Time frame: Up to 12 months after collection visit
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2020 (actual). Primary completion is estimated for Feb 2027, 82 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 82 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.